Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone908-673-9000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$15.28 billion
Profitability
Miscellaneous
Employees8,852
Next Earnings Date1/30/2020 (Estimated)
OptionableOptionable
Celgene (NASDAQ:CELG) Frequently Asked Questions
What is Celgene's stock symbol?
Celgene trades on the NASDAQ under the ticker symbol "CELG."
When did Celgene's stock split? How did Celgene's stock split work?
Celgene's stock split on the morning of Thursday, June 26th 2014. The 2-1 split was announced on Thursday, June 19th 2014. The newly issued shares were issued to shareholders after the market closes on Wednesday, June 25th 2014. An investor that had 100 shares of Celgene stock prior to the split would have 200 shares after the split.
How will Celgene's stock buyback program work?
Celgene declared that its board has initiated a stock repurchase program on Thursday, May 24th 2018, which permits the company to buyback $3,000,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to buy up to 5.4% of its stock through open market purchases. Stock buyback programs are usually a sign that the company's leadership believes its stock is undervalued.
How were Celgene's earnings last quarter?
Celgene Co. (NASDAQ:CELG) issued its earnings results on Thursday, October, 31st. The biopharmaceutical company reported $2.99 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $2.70 by $0.29. The biopharmaceutical company earned $4.52 billion during the quarter, compared to analyst estimates of $4.39 billion. Celgene had a net margin of 34.63% and a return on equity of 78.15%. The firm's revenue for the quarter was up 16.1% on a year-over-year basis. During the same period last year, the firm posted $2.29 EPS. View Celgene's Earnings History.
When is Celgene's next earnings date?
What price target have analysts set for CELG?
18 brokerages have issued 12-month target prices for Celgene's shares. Their forecasts range from $77.00 to $115.00. On average, they anticipate Celgene's share price to reach $97.56 in the next twelve months. This suggests that the stock has a possible downside of 11.6%. View Analyst Price Targets for Celgene.
What is the consensus analysts' recommendation for Celgene?
18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celgene in the last year. There are currently 18 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Celgene.
What are Wall Street analysts saying about Celgene stock?
Here are some recent quotes from research analysts about Celgene stock:
- 1. According to Zacks Investment Research, "Celgene’s lead drug, Revlimid, continues to drive revenues on label expansions and market share gains. Robust performance of psoriasis drug, Otezla, is also boosting performance. The focus is on the merger announcement with large-cap pharma Bristol-Myers worth a whopping $74 billion. Per the terms, Celgene shareholders will receive $50 plus one share of Bristol-Myers and one tradeable Contingent Value Right, which will entitle the holder to receive a cash payment of $9.00 upon the achievement of FDA approval of three candidates (ozanimod, liso-cel and bb2121) within the specified time periods. Meanwhile, the company is also working on label expansion of drugs like Pomalyst/Imnovid, Abraxane and Otezla, among others. Shares have outperformed the industry in the year so far. Estimates are stable ahead of the second-quarter results." (7/23/2019)
- 2. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and $100 12-month price target. Celgene reported a strong 4Q this morning and issued full year 2019 guidance. 4Q revs of ~$4B beat us and consensus on the top line, while adj. EPS of $2.39 also came in above us and consensus at $2.33 and $2.32. Base business trends were surprisingly strong, and management reiterated timelines for all five late- stage pipeline products on track for approval by the end of 2020. We think the key takeaway from the call was that commercial and pipeline execution appear to be back on track with a clear line of sight to the Bristol (BMY, NC) deal closing in 3Q19. We think guidance for 2019 seems conservative." (1/31/2019)
Has Celgene been receiving favorable news coverage?
News articles about CELG stock have been trending somewhat positive on Thursday, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Celgene earned a media sentiment score of 1.7 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Celgene.
Who are some of Celgene's key competitors?
Some companies that are related to Celgene include Amgen (AMGN), Gilead Sciences (GILD), Biogen (BIIB), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), EXACT Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Exelixis (EXEL) and Repligen (RGEN).
What other stocks do shareholders of Celgene own?
Who are Celgene's key executives?
Celgene's management team includes the folowing people:
- Mr. Mark J. Alles, Chairman & CEO (Age 60)
- Mr. David V. Elkins, Exec. VP & CFO (Age 50)
- Mr. Peter N. Kellogg, Exec. VP & Chief Corp. Strategy Officer (Age 63)
- Dr. S. J. Rupert Vessey MA, BM BCh, FRCP, DPhil, Pres of Research & Early Devel. (Age 54)
- Dr. Alise Reicin M.D., Pres of Global Clinical Devel. (Age 58)
Who are Celgene's major shareholders?
Celgene's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (0.41%), Assenagon Asset Management S.A. (0.32%), California Public Employees Retirement System (0.24%), Rhumbline Advisers (0.17%), New York State Teachers Retirement System (0.16%) and Gabelli Funds LLC (0.12%). Company insiders that own Celgene stock include Ernest Mario, Gilla Kaplan, James J Loughlin, John H Weiland, Mark J Alles, Michael D Casey and Terrie Curran. View Institutional Ownership Trends for Celgene.
Which major investors are selling Celgene stock?
CELG stock was sold by a variety of institutional investors in the last quarter, including Close Asset Management Ltd, State of New Jersey Common Pension Fund D, Candriam Luxembourg S.C.A., Trillium Asset Management LLC, Assenagon Asset Management S.A., Klingenstein Fields & Co. LLC, SG Americas Securities LLC and Russell Investments Group Ltd.. Company insiders that have sold Celgene company stock in the last year include James J Loughlin and Terrie Curran. View Insider Buying and Selling for Celgene.
Which major investors are buying Celgene stock?
CELG stock was acquired by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, Tibra Equities Europe Ltd, Syquant Capital Sas, ARP Americas LP, Alpine Group USVI LLC, Alpine Group USVI LLC, Commerzbank Aktiengesellschaft FI and Great West Life Assurance Co. Can. Company insiders that have bought Celgene stock in the last two years include Ernest Mario, John H Weiland and Mark J Alles. View Insider Buying and Selling for Celgene.
How do I buy shares of Celgene?
Shares of CELG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Celgene's stock price today?
One share of CELG stock can currently be purchased for approximately $110.41.
How big of a company is Celgene?
Celgene has a market capitalization of $78.58 billion and generates $15.28 billion in revenue each year. The biopharmaceutical company earns $4.05 billion in net income (profit) each year or $7.61 on an earnings per share basis. Celgene employs 8,852 workers across the globe.View Additional Information About Celgene.
What is Celgene's official website?
How can I contact Celgene?
Celgene's mailing address is 86 MORRIS AVENUE, SUMMIT NJ, 07901. The biopharmaceutical company can be reached via phone at 908-673-9000 or via email at [email protected]
MarketBeat Community Rating for Celgene (NASDAQ CELG)
MarketBeat's community ratings are surveys of what our community members think about Celgene and other stocks. Vote "Outperform" if you believe CELG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CELG will underperform the S&P 500 over the long term. You may vote once every thirty days.
